CIMUS Research Institute and IDIS Research Institute, Santiago de Compostela, Spain.
Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain.
Drug Deliv Transl Res. 2024 Aug;14(8):2026-2031. doi: 10.1007/s13346-024-01608-8.
This note aims to inspire through providing a personal view of the development and potential Drug Delivery Nanocarriers functionalized with polythyleneglycol (PEG). This polymer has been used extensively in Pharmaceutical Technology in a variety of compositions, including polyethylene oxide (PEO)-based surfactants. However, the concept of PEGylation, which started in the 70's, differs from the functionality of a surfactant, already discloses in the 50's. Here, we strictly adhere to the biological functionality of PEGylated nanocarriers intended to have a reduced interaction with proteins and, therefore, modify their biodistribution as well as facilitate their diffusion across mucus and other biological barriers. We analyze how this concept has evolved over the years and the benefit obtained so far in terms of marketed nanomedicines and provide the readers with a prospect view of the topic.
本文旨在通过提供个人观点来激发灵感,探讨聚乙二醇(PEG)功能化的药物传递纳米载体的发展和潜力。该聚合物已广泛应用于制药技术中的各种制剂中,包括基于聚环氧乙烷(PEO)的表面活性剂。然而,PEG 化的概念始于 70 年代,与 50 年代已经出现的表面活性剂的功能不同。在这里,我们严格遵循旨在减少与蛋白质相互作用的 PEG 化纳米载体的生物学功能,从而改变其生物分布,并促进其穿过黏液和其他生物屏障的扩散。我们分析了这一概念多年来的发展演变过程,以及迄今为止在已上市的纳米药物方面获得的益处,并为读者提供了对该主题的展望。